JP5990365B2 - Ｃｄ１３８を標的とする剤及びその使用 - Google Patents

Ｃｄ１３８を標的とする剤及びその使用 Download PDF

Info

Publication number
JP5990365B2
JP5990365B2 JP2010540128A JP2010540128A JP5990365B2 JP 5990365 B2 JP5990365 B2 JP 5990365B2 JP 2010540128 A JP2010540128 A JP 2010540128A JP 2010540128 A JP2010540128 A JP 2010540128A JP 5990365 B2 JP5990365 B2 JP 5990365B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
target antibody
modified target
nbt062
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010540128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509245A (ja
JP2011509245A5 (enExample
Inventor
エルマー・クラウス
クリストフ・ブルエヒャー
ベンジャミン・デルケン
マティアス・ゲルマー
シュテファン・ツェン
フランク・オステロート
クリストフ・ウーヘレク
ジルケ・アイグナー
グレゴール・シュルツ
Original Assignee
バイオテスト・アクチエンゲゼルシヤフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40456217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5990365(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイオテスト・アクチエンゲゼルシヤフト filed Critical バイオテスト・アクチエンゲゼルシヤフト
Publication of JP2011509245A publication Critical patent/JP2011509245A/ja
Publication of JP2011509245A5 publication Critical patent/JP2011509245A5/ja
Application granted granted Critical
Publication of JP5990365B2 publication Critical patent/JP5990365B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010540128A 2007-12-26 2008-12-23 Ｃｄ１３８を標的とする剤及びその使用 Expired - Fee Related JP5990365B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1663007P 2007-12-26 2007-12-26
US61/016,630 2007-12-26
PCT/EP2008/068266 WO2009080829A1 (en) 2007-12-26 2008-12-23 Agents targeting cd138 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015022983A Division JP2015143228A (ja) 2007-12-26 2015-02-09 Ｃｄ１３８を標的とする剤及びその使用

Publications (3)

Publication Number Publication Date
JP2011509245A JP2011509245A (ja) 2011-03-24
JP2011509245A5 JP2011509245A5 (enExample) 2012-02-16
JP5990365B2 true JP5990365B2 (ja) 2016-09-14

Family

ID=40456217

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010540128A Expired - Fee Related JP5990365B2 (ja) 2007-12-26 2008-12-23 Ｃｄ１３８を標的とする剤及びその使用
JP2015022983A Withdrawn JP2015143228A (ja) 2007-12-26 2015-02-09 Ｃｄ１３８を標的とする剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015022983A Withdrawn JP2015143228A (ja) 2007-12-26 2015-02-09 Ｃｄ１３８を標的とする剤及びその使用

Country Status (23)

Country Link
US (2) US9221914B2 (enExample)
EP (2) EP2238168B8 (enExample)
JP (2) JP5990365B2 (enExample)
KR (1) KR101626416B1 (enExample)
CN (1) CN101952315B (enExample)
AR (1) AR069981A1 (enExample)
AU (1) AU2008339910B2 (enExample)
BR (1) BRPI0821447A2 (enExample)
CA (1) CA2710453C (enExample)
CR (1) CR11593A (enExample)
DK (1) DK2238168T3 (enExample)
ES (2) ES2748299T3 (enExample)
HK (1) HK1203973A1 (enExample)
HR (1) HRP20140604T1 (enExample)
IL (1) IL206554A (enExample)
MX (1) MX341344B (enExample)
PL (2) PL2801584T3 (enExample)
PT (1) PT2238168E (enExample)
RU (1) RU2537265C2 (enExample)
SI (1) SI2238168T1 (enExample)
TW (1) TWI552759B (enExample)
WO (1) WO2009080829A1 (enExample)
ZA (1) ZA201004325B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10648554B2 (en) 2014-09-02 2020-05-12 Polaris Industries Inc. Continuously variable transmission
US10697532B2 (en) 2016-12-22 2020-06-30 Polaris Industries Inc. Housing for a transmission
US11543005B2 (en) 2018-03-19 2023-01-03 Polaris Industries Inc. Electronic CVT with friction clutch
US11578793B2 (en) 2018-03-19 2023-02-14 Polaris Industries Inc. Continuously variable transmission

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
KR20100097753A (ko) * 2007-12-26 2010-09-03 바이오테스트 아게 Ｃｄ138 표적성 면역접합체 및 이의 용도
AU2008339910B2 (en) 2007-12-26 2014-01-09 Biotest Ag Agents targeting CD138 and uses thereof
KR101579218B1 (ko) * 2007-12-26 2015-12-21 바이오테스트 아게 Ｃｄ138 발현성 종양 세포에 대한 표적화를 개선시키기 위한 방법 및 물질
AU2013201618B2 (en) * 2009-05-06 2016-06-02 Biotest Ag Uses of immunoconjugates targeting CD138
SG10201401976YA (en) * 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
KR20140100571A (ko) * 2011-12-08 2014-08-14 바이오테스트 아게 Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
SI2766048T1 (sl) 2012-10-12 2015-03-31 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
ES2671004T3 (es) * 2013-03-07 2018-06-04 Baylor College Of Medicine Dirección a CD138 en cáncer
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
WO2015096982A1 (de) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3682904A1 (en) 2014-06-30 2020-07-22 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CN107075483A (zh) 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 用于过继细胞治疗的工程改造的细胞
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2015337858B2 (en) 2014-10-29 2020-09-24 Teva Pharmaceuticals Australia Pty Ltd. Interferon alpha2b variants
TWI588259B (zh) * 2015-03-06 2017-06-21 Methods for screening antigen-specific fusion tumor cells
MX392478B (es) 2015-06-22 2025-03-24 Bayer Pharma AG Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
RU2611685C2 (ru) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
CA3047489A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) having enzymatically cleavable groups
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
JP7254029B2 (ja) * 2017-04-26 2023-04-07 田辺三菱製薬株式会社 Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用
CN110809717A (zh) 2017-05-05 2020-02-18 悉尼理工大学 癌症预后的方法
PT3538645T (pt) 2017-06-20 2021-04-15 Inst Curie Células imunológicas deficitárias em suv39h1
SG11202002248TA (en) * 2017-10-02 2020-04-29 Visterra Inc Antibody molecules to cd138 and uses thereof
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
PL3720883T3 (pl) 2017-12-05 2023-09-11 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Komórki t zawierające chimeryczne receptory antygenowe anty-cd38 i anty-cd138 oraz ich zastosowania
EP3720882A4 (en) 2017-12-05 2021-10-27 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center T LYMPHOCYTES INCLUDING TWO DIFFERENT ANTIGENIC CHEMERICAL RECEPTORS AND THEIR USES
MX2020005906A (es) 2017-12-08 2020-10-22 Juno Therapeutics Inc Marcadores fenotipicos para terapia celular y metodos relacionados.
MX2020005908A (es) 2017-12-08 2020-10-07 Juno Therapeutics Inc Proceso para producir una composicion de celulas t modificadas.
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
US20220111065A1 (en) 2018-05-23 2022-04-14 Adc Therapeutics Sa Molecular adjuvant
BR112021002245A2 (pt) 2018-08-09 2021-05-04 Juno Therapeutics Inc métodos para avaliar ácidos nucleicos integrados
JP7742773B2 (ja) 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
WO2020257289A2 (en) * 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
JP7735249B2 (ja) 2019-07-23 2025-09-08 ムネモ・セラピューティクス Ｓｕｖ３９ｈ１欠損免疫細胞
KR102287180B1 (ko) * 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
EP4132542A2 (en) 2020-04-10 2023-02-15 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
CN116096864A (zh) 2020-07-30 2023-05-09 居里研究所 Socs1缺陷的免疫细胞
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
US20250304915A1 (en) 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
MA67298A1 (fr) 2022-02-18 2025-03-28 Rakuten Medical, Inc. Molécules d'anticorps anti-ligand de mort cellulaire programmée 1 (pd-l1), polynucléotides de codage et méthodes d'utilisation
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2024038854A1 (ja) 2022-08-15 2024-02-22 Ａｇｃ株式会社 フルオロアルケン共重合体
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
CN115960231A (zh) * 2022-09-28 2023-04-14 合肥天港免疫药物有限公司 抗cd138的抗体及其应用
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) * 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) * 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) * 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) * 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) * 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) * 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4761111A (en) * 1981-09-18 1988-08-02 Brown Andrew M Automobile lifting and towing equipment
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4418064A (en) * 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3751319T2 (de) 1986-10-09 1996-02-29 Neorx Corp VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
AU648313B2 (en) * 1990-04-25 1994-04-21 Pharmacia & Upjohn Company Novel CC-1065 analogs
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
EP0815096A4 (en) * 1995-03-10 1998-07-08 Hauser Chemical Res Inc EPOXIDE OF CEPHALOMANNIN, ITS ANALOGS, AND PROCESS FOR PREPARING THE SAME
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
AU7378096A (en) * 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
CA2420193A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) * 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
ES2545745T3 (es) * 2002-05-02 2015-09-15 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
PL224787B1 (pl) * 2003-01-22 2017-01-31 Roche Glycart Ag Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
US7449303B2 (en) 2003-05-02 2008-11-11 Health Research, Inc. Use of JAG2 expression in diagnosis of plasma cell disorders
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101565721B1 (ko) * 2003-07-21 2015-11-03 이뮤노젠 아이엔씨 씨에이6 항원 특이적 세포독성 접합체 및 이를 사용하는 방법
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
WO2005063981A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗cd40抗体の変異体
CA2567520A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
PT2311874T (pt) 2004-07-22 2017-08-25 Univ Erasmus Med Ct Rotterdam Moléculas de ligação
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
ES2387312T3 (es) * 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
EP1874959A2 (en) 2005-04-07 2008-01-09 Novartis Vaccines and Diagnostics, Inc. CANCER-RELATED GENES (PTPepsilon)
AU2006236489C1 (en) 2005-04-15 2012-04-12 Immunogen, Inc. Elimination of heterogeneous or mixed cell population in tumors
US20070054332A1 (en) 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
US20100021473A1 (en) 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
US20100291105A1 (en) 2006-05-03 2010-11-18 Elke Pogge Von Strandmann Agent for the treatment of malignant diseases
KR101579218B1 (ko) 2007-12-26 2015-12-21 바이오테스트 아게 Ｃｄ138 발현성 종양 세포에 대한 표적화를 개선시키기 위한 방법 및 물질
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
AU2008339910B2 (en) 2007-12-26 2014-01-09 Biotest Ag Agents targeting CD138 and uses thereof
SG10201401976YA (en) 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10648554B2 (en) 2014-09-02 2020-05-12 Polaris Industries Inc. Continuously variable transmission
US11306815B2 (en) 2014-09-02 2022-04-19 Polaris Industries Inc. Continuously variable transmission
US11879542B2 (en) 2014-09-02 2024-01-23 Polaris Industries Inc. Continuously variable transmission
US12072018B2 (en) 2014-09-02 2024-08-27 Polaris Industries Inc. Continuously variable transmission
US10697532B2 (en) 2016-12-22 2020-06-30 Polaris Industries Inc. Housing for a transmission
US11543005B2 (en) 2018-03-19 2023-01-03 Polaris Industries Inc. Electronic CVT with friction clutch
US11578793B2 (en) 2018-03-19 2023-02-14 Polaris Industries Inc. Continuously variable transmission
US11649889B2 (en) 2018-03-19 2023-05-16 Polaris Industries Inc. Continuously variable transmission
US12007014B2 (en) 2018-03-19 2024-06-11 Polaris Industries Inc. Continuously variable transmission
US12092198B2 (en) 2018-03-19 2024-09-17 Polaris Industries Inc. Continuously variable transmission

Also Published As

Publication number Publication date
EP2238168B1 (en) 2014-06-11
EP2238168B8 (en) 2014-07-23
DK2238168T3 (da) 2014-08-25
KR101626416B1 (ko) 2016-06-01
AR069981A1 (es) 2010-03-03
HK1149033A1 (en) 2011-09-23
BRPI0821447A2 (pt) 2015-06-16
RU2010130994A (ru) 2012-02-10
PL2238168T3 (pl) 2014-11-28
HK1203973A1 (en) 2015-11-06
CR11593A (es) 2011-06-07
PL2801584T3 (pl) 2019-12-31
US20090175863A1 (en) 2009-07-09
CA2710453A1 (en) 2009-07-02
TW200934511A (en) 2009-08-16
CA2710453C (en) 2019-07-02
ES2475201T3 (es) 2014-07-10
CN101952315B (zh) 2015-04-01
JP2011509245A (ja) 2011-03-24
IL206554A (en) 2015-09-24
AU2008339910B2 (en) 2014-01-09
ZA201004325B (en) 2011-03-30
TWI552759B (zh) 2016-10-11
RU2537265C2 (ru) 2014-12-27
EP2801584B1 (en) 2019-07-10
PT2238168E (pt) 2014-07-18
US20160185854A1 (en) 2016-06-30
CN101952315A (zh) 2011-01-19
HRP20140604T1 (hr) 2014-09-12
EP2238168A1 (en) 2010-10-13
EP2801584A1 (en) 2014-11-12
JP2015143228A (ja) 2015-08-06
US9221914B2 (en) 2015-12-29
ES2748299T3 (es) 2020-03-16
WO2009080829A1 (en) 2009-07-02
KR20100100989A (ko) 2010-09-15
MX2010007100A (es) 2010-12-06
AU2008339910A1 (en) 2009-07-02
MX341344B (es) 2016-08-16
IL206554A0 (en) 2010-12-30
SI2238168T1 (sl) 2014-09-30

Similar Documents

Publication Publication Date Title
JP5990365B2 (ja) Ｃｄ１３８を標的とする剤及びその使用
JP5817034B2 (ja) Ｃｄ１３８を標的とする免疫複合体及びその使用
TWI450726B (zh) 用於改良靶定於表現ｃｄ１３８之腫瘤細胞的方法及藥劑
HK1149033B (en) Agents targeting cd138 and uses thereof
HK1149034B (en) Immunoconjugates targeting cd138 and uses thereof
AU2013203245A1 (en) Agents targeting CD138 and uses thereof
AU2013204492A1 (en) Immunoconjugates targeting CD138 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150304

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160815

R150 Certificate of patent or registration of utility model

Ref document number: 5990365

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees